Brivaracetam FDA-Approved for Pediatric Seizures
Brivaracetam, available in the form of tablets, oral solution and intravenous fluid (IV) is now FDA-approved for the treatment of partial-onset seizures in children as young as one month. Brivaracetam IV formulation is the only IV formulation approved in last 7 years to treat partial-onset seizures in children one month of age and older. As […]
Association between COVID-19 and New-onset Epileptic Seizures
Name – American Academy of Neurology Annual Meeting (AAN 2021) (April 17 – April 22, 2021) Mode – Virtual A retrospective study conducted on COVID-19 patients, found a three times higher risk of novel seizures in those without a known history of epilepsy. Patients with new-onset seizures had longer hospital stays by 15 days and […]
Predictors of Late Seizure Relapse After Epilepsy Surgery
Based on the findings of a new study, incomplete resection and epilepsy onset during first year of life were found to be key predictors of late seizure relapse following epilepsy surgery. In this retrospective analysis, around 99 patients who experienced a seizure relapse after 2 years of seizure freedom were matched with controls having long-term […]
Cannabidiol Gel for Children with Encephalopathies
In children with developmental and epileptic encephalopathies, use of topical cannabidiol gel along with antiseizure therapy can improve quality of life. The safety and tolerability of cannabidiol gel was studied on 48 children, aged 3 to 13 years, in an open-label, non-randomized controlled trial. After the initial month of baseline and titration period, patients were […]
Levetiracetam and Lacosamide in epilepsy patients
Introduction Conventional anti‑epileptic first‑line drugs can control the seizures of most patients with epilepsy, but persistent seizures occur in more than 30% of patients. Lacosamide, an antiepileptic drug, has been used as an adjuvant treatment for partial or systemic epilepsy. Objective To evaluate the therapeutic effect of levetiracetam combined with Lacosamide in patients with epilepsy. […]
Management of drug-resistant focal epilepsy with Levetiracetam
Introduction Epilepsy affects over 70 million people worldwide. With the evolving resistance of focal epilepsy, there is need for add-on therapies for better clinical outcomes. Objectives To evaluate the effectiveness of levetiracetam as an add-on treatment for people with drug-resistant focal epilepsy. Search methods The Cochrane Register of Studies (CRS Web, which includes the Cochrane […]